Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.79 |
| ▸ | AR | P10275 | 3/20 | 0.79 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | GUSB | P08236 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660200 | 1.00 | MAOB (0.79) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL19745 | 0.89 | MAOB (1.00) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL29470801 | 0.89 | MAOB (1.00) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL29843289 | 0.89 | MAOB (1.00) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL12660199 | 0.89 | MAOB (1.00) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL12189591 | 0.89 | MAOB (1.00) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL27435617 | 0.87 | MAOB (0.96) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL22715765 | 0.87 | MAOB (0.96) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL27291349 | 0.87 | MAOB (0.96) | MAOBADORA3ARCYP19A1KDM4E | |
| Flavanone SCHEMBL11733114 | 0.87 | MAOB (0.96) | MAOBADORA3ARCYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108113984-A | Purposes of the SHP2 inhibitor in anti-tumor drug is prepared | 中国科学院成都生物研究所 | 2018-06-05 | — | — | CN | claimed |
| CN-108113984-A | Purposes of the SHP2 inhibitor in anti-tumor drug is prepared | 中国科学院成都生物研究所 | 2018-06-05 | — | — | CN | disclosed |
| US-20110117649-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-19 | — | — | US | disclosed |
| US-7851640-B2 | Catalytic enantioselective synthesis of flavanones and chromanones | NORTHWESTERN UNIVERSITY (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090259055-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259055-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | RNGTT, CDK20, TBXAS1 | MAOB 458/4885ADORA3 1130/4885AR 889/4885 |
| US-20110117649-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | RNGTT, CDK20, TBXAS1 | MAOB 458/4885ADORA3 1130/4885AR 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.